Tag
Biologics & Biosimilars
3 articles
Aurobindo Pharma Q1 FY27 Revenue Up 16% to ₹9,150 Cr
Aurobindo Pharma reported Q1 FY27 consolidated revenue growth of 16% YoY to ₹9,150 crores with an EBITDA margin of 21%.
The company completed the Lannett acquisition, strengthening its US platform in
Shilpa Medicare FY26 Profit Surges 211% to ₹243 Crores
Shilpa Medicare reported record FY26 performance with 211% PAT growth to ₹243 crores and 18% revenue growth to ₹1,549 crores across API, formulations, and biologics segments.
The company issued 1:1 bo
Emcure Q1 FY27 Net Profit Jumps 36% YoY
Emcure Pharmaceuticals reported Q1 FY27 revenue growth of 22.8% YoY to ₹2,580 crore and a 36.2% rise in PAT to ₹292 crore.
International business surged 34.2% driven by Europe, Canada, and strong ARV